Adagrasib improves on docetaxel in previously treated NSCLC

Manageable safety profile with early efficacy of Tec-DR in NDMM

Inavolisib, palbociclib, fulvestrant combo shows sustained benefit beyond disease progression in HER2‑negative metastatic breast cancer

Atezolizumab versus placebo in combination with bevacizumab and non-platinum-based chemotherapy in recurrent ovarian cancer

Looking at real world evidence on PSA testing in prostate cancer

Ciltacabtagene autoleucel benefit for lenalidomide-refractory FHR multiple myeloma

Immunotherapy promise for gynaecologic extra-renal clear cell carcinomas

Ivonescimab benefit for EGFR mutant NSCLC patients who failed TKI therapy

Bortezomib and dexamethasone demonstrate efficacy benefit in key subgroups vs daratumumab, bortezomib, and dexamethasone in RRMM

HER2DX assay and survival outcomes: An individual-patient level meta-analysis of 2,031 patients with HER2-positive BC

CAR-T, bispecifics or ADCs in late-stage RRMM

Complementing clinical trials: Investigating the value of real world evidence with insights from TE NDMM